Astellas Pharma Global Development, Inc.

This study tests a drug called zolbetuximab for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). The drug works by attaching to that protein and helping the immune system attack the tumor. Participants receive zolbetuximab a…

This early-stage study tests a new drug, zolbetuximab, combined with standard chemotherapy in people with advanced pancreatic cancer that has spread. The drug targets a protein on cancer cells to help the immune system attack them. The main goals are to check safety and find the …

This study tests a liquid form of mirabegron, a drug already approved for older children and adults, in children aged 6 months to 3 years who have bladder problems due to nerve damage (neurogenic detrusor overactivity). The goal is to see if the drug helps the bladder hold more u…

This study tests whether adding zolbetuximab (a drug that targets a protein called CLDN18.2 found in many pancreatic tumors) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 393 adults whose cancer has spread and has the CLDN18.2 marker w…

This study tests a new drug, ASP1570, in adults with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with other cancer therapies like pembrolizumab, pemetrexed, and carboplatin. The goal is to find a safe dose and see if it helps c…

This study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with a fast-growing type of acute myeloid leukemia (AML) who cannot have standard chemotherapy. The goal is to find the best dose and see how well the treatment con…

This study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer without their cancer growing. About 500 adults…

This study tests an experimental drug, enfortumab vedotin, in people with advanced solid tumors that have spread. The main goal is to see if the drug can shrink tumors. About 329 adults with various solid tumors will take part. The drug is given by IV and aims to control the dise…

This study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy can slow down or delay cancer growth in people with advanced stomach or gastroesophageal junction cancer. About 565 adults whose …

This study follows about 1,000 women in menopause who are starting a non-hormonal treatment for bothersome hot flashes and night sweats. Researchers will check if symptoms improve after 12 weeks, and also look at sleep, work productivity, and overall well-being. The goal is to se…

This early-phase study tests a new shot (ASP2390) for adults with house dust mite allergies. The main goal is to see if the shot is safe and tolerable. Researchers will also measure changes in allergy-related antibodies. The study involves 28 participants and multiple doses.

This study tests fezolinetant, a non-hormonal drug, for reducing hot flashes in women with hormone-positive breast cancer who are on hormone therapy. About 984 women with moderate to severe hot flashes will take either fezolinetant or a placebo daily for a year. The goal is to se…